PORTLAND, Ore., March 7 /PRNewswire-FirstCall/ -- Bioject Medical Technologies Inc. , a leading developer of needle-free drug delivery systems, today announced that it has made the initial commercial product delivery of the Derma-Vac(TM) NF Transdermal Vaccination System to Merial Limited ("Merial"), a world-leading animal health company, for use with its SWIVAX(TM)-MH, the first and only USDA approved swine vaccine administered by a needle-free transdermal delivery system, which is available exclusively from Merial.
The Derma-Vac(TM) NF device is designed for several production animals and is being used initially by Merial in the swine market for the SWIVAX(TM)-MH vaccine to aid in the reduction and control of respiratory disease due to Mycoplasma hyopneumoniae (M. hyo). The device uses a multi-dose vial, compressed air canister and marking pen. The device is designed to give 2,000 injections per hour and marks the swine with ink upon injection, indicating that the injection has been delivered. The device comes with four nozzle sizes to address the full range of swine delivery requirements from piglet to sow.
"We are pleased to have delivered the commercial launch Derma-Vac(TM) NF devices to Merial for use with its new swine vaccine," said Jerald S. Cobbs, Chairman of Bioject. "This device, which utilizes the Biojector(R)2000 technology, is our first product that gives multiple injections using a multi-dose vial. We look forward to this device being used by Merial with other production animals."
About Bioject
Bioject Medical Technologies Inc., based in Portland, Oregon, is an innovative developer and manufacturer of needle-free drug delivery systems. Needle-free injection works by forcing medication at high speed through a tiny orifice held against the skin. This creates a fine stream of high-pressure fluid penetrating the skin and depositing medication in the tissue beneath. The Company is focused on developing mutually beneficial agreements with leading pharmaceutical, biotechnology, and veterinary companies.
This press release contains a forward-looking statement within the meaning of the Private Securities Litigation Reform Act of 1995, including statements regarding the use of the Derma-Vac(TM) NF device by Merial with other production animals. Such forward-looking statements involve known and unknown risks, uncertainties and other factors that may cause the actual results, performance or achievements of the Company, or industry results, to be materially different from any future results, performance, or achievements expressed or implied by such forward-looking statements. Such risks, uncertainties and other factors include, without limitation, the risk that the products will not be accepted by the market; the risk that the Company may be unable to produce its products at a unit cost necessary for the products to be competitive in the market; and the risk that the Company may be unable to comply with the extensive government regulations applicable to its business. Readers of this press release are referred to the Company's filings with the Securities and Exchange Commission, including the Company's reports on Form 10-K and Forms 10-Q for further discussions of factors that could affect the Company's business and its future results. Forward-looking statements are based on the estimates and opinions of management on the date the statements are made. The Company assumes no obligation to update forward-looking statements if conditions or management's estimates or opinions should change.
For more information on Bioject, visit www.bioject.com.
Bioject Medical Technologies Inc.CONTACT: Jerald S. Cobbs, Chairman, +1-503-692-8001, ext. 4161, or ChrisFarrell, Vice President of Finance, +1-503-692-8001, ext. 4132, both ofBioject Medical Technologies Inc.
Web site: http://www.bioject.com//
